2026 Faculty

Sylvie Lorenzen

Klinikum Rechts der Isar, Technische Universität München | Germany

Prof Lorenzen is a consultant at the Department of Hematology and Oncology and Head of the Early Clinical Trial Unit, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany. Prof Lorenzen is chair of the Gastric Cancer Task Force of the Arbeitsgemeinschaft Internistische Onkologie (AIO; German Cancer Society), and a member of the Educational Steering Committee of the European Society for Medical Oncology (ESMO) and the Bavarian Ethics Commission. She is also designated Investigator of the German Consortium for Translational Research (DKTK), the Spokesperson and Coordinator of the German Gastric- and Esophageal Cancer Guidelines (S3-Leitlinien), First-author of the German Onkopedia Guidelines, Coauthor of the ESMO Gastroesophageal Cancer Guidelines (in preparation) and speaker for the BZKF Gastroesophageal Working Group.

Iain Tan

National Cancer Centre Singapore | Singapore

Dr. Iain Tan is a Senior Consultant Medical Oncologist, leading the colorectal cancer service in the GI Oncology Team at the Department of Medical Oncology, National Cancer Centre Singapore. Dr Iain Tan, a clinician-scientist at A*STAR’s Genome Institute of Singapore (GIS), was awarded the prestigious Singapore Youth Award 2014. Dr Tan has been recognized for his contributions as a consultant oncologist at the National Cancer Singapore (NCCS) and research scientist at GIS, and for his efforts to cultivate an environment conducive for translational research. Dr Tan’s research focuses on new ways in the early detection and diagnosis of colorectal cancer.

Shaheenah Dawood

Mediclinic City Hospital | United Arab Emirates

Shaheenah Dawood is a Consultant medical oncologist and associate professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals including the Journal of Clinical Oncology. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the UAE Cancer Congress that is held annually in Dubai and is co-president of the Asia pacific breast cancer summit (APBCS) and Asia pacific gastrointestinal cancer summit (APGCS).

Stephen Chan

Chinese University of Hong Kong | Hong Kong S.A.R

Stephen Lam CHAN is a Clinical Professor in the Department of Clinical Oncology at the Chinese University of Hong Kong (CUHK). He is renowned for his clinical and translational research on hepatobiliary and pancreatic cancers. Prof. Chan has authored over 270 papers published in peer-reviewed journals. Internationally, he has served on the scientific committees of ASCO and ESMO conferences, and is currently the President of the International Liver Cancer Association (ILCA). Prof. Chan is an associate editor for journals such as the Journal of Hepatology. Locally, he is a board director of the CUHK Medical Centre and the Assistant Dean (Health Systems) of the Faculty of Medicine at CUHK. He also established the Hand in Hand Cancer Foundation, a charity dedicated to serving patients in need.

Herdee Luna

Philippine Society of Medical Oncology | Philippines

Dr Herdee Gloriane C. Luna is a graduate of University of Santo Tomas, Faculty of Medicine and Surgery. She completed her Internal Medicine Residency and Medical Oncology Fellowship training at the National Kidney and Transplant Institute (NKTI). She is the current Research Head at the NKTI Section of Medical Oncology, Executive Action Team - Oncology Manager at the Philippine Cancer Society, P SubCommittee Head on National Affairs (External Affairs Committee) at the Philippine Society of Medical Oncology, Philippine Council representative of the Asian Oncology Society and Immediate Past President of the Philippine Society of Oncologists. Her research interest focuses on cancer proteomics and cancer medicine access. She’s a member of the American Society of Clinical Oncology, European Society for Medical Oncology, Philippine College of PHysicians and is affiliated with St. Luke’s Medical Center, Quezon City and Lung Center of the Philippines.

Chiun Hsu

National Taiwan University Hospital | Taiwan (PRC)

Dr. Chiun Hsu received his medical degree from College of Medicine, National Taiwan University (NTUCM) in 1992 and his PhD degree from the Graduate Institute of Clinical Medicine, NTUCM in 2004. He serves as Associate Dean and Director of Center of Faculty Development, NTUCM. His major research interest is clinical and translational research of new drug development for hepatobiliary cancers and his favourite hobby Chinese calligraphy.

Shailesh Shrikhande

Tata Memorial Hospital | India

Shailesh V. Shrikhande is the Chief Executive of Tata Cancer Care Foundation (TCCF), Director of GI and HPB Cancer Surgery at Gleneagles Hospital, Parel, Mumbai, and a Consultant Surgeon at Breach Candy Hospital and Shrikhande Clinic, Mumbai, India. He is also the Officer on Special Duty at Tata Memorial Centre. Previously, he was Head of GI and HPB Surgery (2010-2025) and Deputy Director of Tata Memorial Hospital (2018-2025), Mumbai.

Bhawna Sirohi

BALCO Medical Centre | India

Dr Bhawna Sirohi is the Medical Director at BALCO Medical Centre, Raipur and a Breast Medical Oncologist. She has more than two decades of experience as an oncologist in UK & India. Having qualified as an oncologist from Tata Memorial Centre, Mumbai, she further completed her training at Royal Marsden NHS Foundation Trust, UK. She has published more than 150 papers in national and international journals and has lectured worldwide. She has been involved in varied capacities to create cancer awareness in India be it through cancer screening camps in various states to the initial setting up of cancer centers in the private or public sector to enabling protocols and procedures for safe care of patients. She is deeply involved with charities like CanSupport and has even set up a charity New India Cancer Charity Initiative or NICCI.

Toh Han Chong

National Cancer Centre Singapore | Singapore

Prof. Toh is Senior Consultant and Deputy Chief Executive Officer (Strategic Partnerships), Division of Medical Oncology, National Cancer Centre Singapore. He graduated from the University of London, UK with an intercalated Bachelor of Science in ‘Infection and Immunity’ from St Mary’s Hospital Medical School and qualified as a medical doctor from University of Cambridge, UK. Dr Toh obtained his Fellowship of the Royal College of Physicians in 2003. He received his medical oncology fellowship training at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston USA, and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. He is also an alumni at the Harvard Business School General Management Program. Dr Toh is a recipient of the National Senior Clinician Scientist Award in 2017 and National Medical Excellence Award (NMEA) in 2018 for his pioneering work in cell and immunotherapy for cancer. He leads the NMRC LCG VICTORY (Virus-Induced Cancers Translational Oncology and immunologY) grant. As an Associate Professor and College Master at the Duke-NUS Graduate Medical School, Dr Toh is actively involved in medical education and training. He is the founding Chairman of the Singapore Society of Oncology Cancer Immunotherapy Consortium, co-founder of the Asia Pacific Gastroenterology Cancer Summit (APGCS), and faculty in the Cancer Immunology for the European Society of Medical Oncology (ESMO). Dr Toh has published over 132 peer review journal papers to date.

Kaina Chen

Singapore General Hospital | Singapore

Dr Chen Kaina is an accredited specialist in the field of Gastroenterology & Hepatology. She obtained her specialist accreditation in Gastroenterology and holds a Master of Clinical Investigation from the National University of Singapore. She manages a wide range of gastrointestinal conditions including disorders of the oesophagus, stomach, and intestines, and has a clinical interest in hepatology, including liver cirrhosis, viral hepatitis, metabolic liver disease, portal hypertension and liver cancer as part of the multi-disciplinary management. Dr Chen is actively engaged in clinical and translational research, with a focus on liver cancer and early detection in Asian populations. She has received competitive research funding, including SingHealth Pitch-for-Fund and National Medical Research Council (NMRC) seed grants. She is a regular speaker at local and international conferences and is actively involved in medical education. She holds an academic appointment as Clinical Assistant Professor at Duke-NUS Medical School.

Kai-Keen Shiu

UCL Cancer Institute | United Kingdom

Dr. Shiu is a Consultant in the Gastrointestinal Oncology Unit at University College London Hospital NHS Foundation Trust and Honorary Associate Professor at the UCL Cancer Institute. His research interests include immunotherapy for GI malignancies and Cancer of Unknown Primary, as well as the development of early and late phase novel cancer clinical trial designs. He is the Principal Investigator of the UCL/UCLH Gastrointestinal Cancer Translational Research Biobank and member of ASCO, AACR, ESMO and the Association of Cancer Physicians UK.

Han Shuting

National Cancer Centre Singapore | Singapore

Dr. Han Shuting is a Consultant Medical Oncologist at the National Cancer Centre Singapore (NCCS). She graduated with Bachelor of Arts (Honours) from Christ’s College, Cambridge in 2010 and Bachelor of Medicine and Surgery (MBBChir) from Cambridge School of Clinical Medicine in 2013. Subsequently, she obtained her MRCP (UK) and MMed (Int. Med) accreditation in 2015. She completed her medical oncology training in NCCS in 2019. She is currently pursuing a PhD at the National University of Singapore under the National Medical Research Council (NMRC) research training fellowship award. She sub-specialises in gastrointestinal cancers and her areas of research include colorectal cancers, viral-driven cancers and immuno-oncology.

Evelyn Wong

DUKE NUS, Sengkang General Hospital, National Cancer Centre Singapore | Singapore

Dr Evelyn Wong Yi Ting is a Consultant Medical Oncologist at NCCS and Sengkang General Hospital, specialising in gastrointestinal and hepatobiliary cancers, with a focus on early onset colorectal cancer and digital oncology. She is the founder of AYABytes, a patient centred mobile app for adolescents and young adults with cancer, launched by NCCS in 2023. She trained at the National University of Singapore and NCCS and completed her GI oncology fellowship at UCLH in 2025, where she gained expertise in complex malignancies, contributed to clinical trials, and established a service for early onset GI cancers. She remains an Honorary Consultant at UCLH. Dr Wong’s work emphasises value based care, digital innovation, and reducing global cancer disparities. She has held leadership roles in value driven care, contributed to global health initiatives across Asia, and supports oncology education as a Clinical Assistant Professor. She is actively involved in teaching and has received awards recognising her contributions to medical education.

Joan Choo

National University Cancer Institute | Singapore

Dr Joan Choo is a Consultant Medical Oncologist in the Department of Haematology–Oncology at the National University Cancer Institute, Singapore (NCIS), where she specialises in gastrointestinal and hepatobiliary cancers. She is also part of the Haematology–Oncology Research Group (HORG), which runs early-phase clinical trials. Dr Choo has a keen interest in clinical and translational research in gastrointestinal cancers, with multiple publications in peer-reviewed journals in this area. She currently serves as the Clinical Lead for adoptive cell therapies in solid tumours at NCIS.

Robert Walsh

National University Cancer Institute | Singapore

Dr Robert Walsh obtained his undergraduate medical degree from the University of Cambridge, England before undertaking Foundation training at the University Hospitals of Leicester NHS Trust. He has worked in the Singapore health system since 2013 and obtained his postgraduate qualifications from the Royal College of Physicians (UK) in 2015. Dr Walsh subsequently completed postgraduate residency training in Internal Medicine and Medical Oncology at the National University Health System, Singapore. His areas of clinical and research interests include gastrointestinal cancer and precision oncology.

Wang Fuqiang

National Cancer Centre Singapore | Singapore

Dr. Wang is a consultant radiation oncologist at the Division of Radiation Oncology, National Cancer Centre Singapore. His clinical practice focuses on colorectal, hepato pancreato biliary and upper gastrointestinal cancers.

Thomas Yau

The University of Hong Kong | Hong Kong S.A.R

Dr. Yau is a Clinical Associate Professor at the University of Hong Kong and Principal Investigator at the State Key Laboratory for Liver Disease. Specializing in gastrointestinal oncology and early-phase translational research, he developed the Hong Kong Liver Cancer classification, reshaping treatment paradigms. With 200+ publications (including The Lancet), an H-index of 74, and 39,000+ citations, his work has enabled global drug approvals for advanced liver cancer. He holds leadership roles in ESMO, SITC, and APPLE, and serves on editorial boards including the Journal of Clinical Oncology.

Matthew Ng

National Cancer Centre Singapore | Singapore

A/Prof Matthew Ng is the Head of GI Oncology at the National Cancer Centre Singapore and co-chairs the GI cancers service line delivery within the SingHealth Academic Medical Health Cluster. He obtained his PhD from the Institute of Cancer Research (London, UK) and research interests are in developing novel treatments for GI cancers particularly peritoneal directed therapies for upper GI cancers and as well as Early Phase cancer drug development. He is the oncology lead for Upper GI cancers at NCCS and is part of the Singapore Gastric Cancer Consortium, Singapore Peritoneal Oncology Study Group and Singapore Translational Cancer Consortium. As the Clinical Director of the Investigational Medicine Unit (Singhealth) he oversees the conduct of inpatient early phase and healthy volunteer trials.

Kuang Ming

Cancer Center and Hepato-pancreato-biliary Surgery Center, Sun Yat-sen University | China

Dr. Kuang is a Professor in Hepatobiliary surgery and Interventional Ultrasound, and Director of Cancer Center and Hepato-pancreato-biliary Surgery Center in FAH-SYSU. As a doctor, Dr. Kuang majors in minimally invasive treatments for cancer and is interested in the mechanism, prevention and treatment of liver cancer recurrence and metastases, and precision cancer research including immunotherapy. He has published more than 100 original articles on Ann Oncol, Nature Communication, Hepatology, Radiology, and Clinical Cancer Research in recent years. Dr. Kuang is nowadays one of the leading experts in the field of tumor ablation in China.

Pierce Chow

National Cancer Centre Singapore | Singapore

Prof. Pierce Chow is Director of the Comprehensive Liver Cancer Clinic at the National Cancer Centre Singapore, Senior Consultant Surgeon in HPB and Transplant Surgery at the Singapore General Hospital and Professor and Program Director at Duke-NUS Medical School Singapore. He is the President of the Asia-Pacific Primary Liver Cancer Expert (APPLE) Association (2026-28). In addition to managing a busy HPB surgical oncology service, Prof. Chow has conducted multiple clinical trials in HCC as protocol chair of the Asia-Pacific HCC (AHCC) trials group including the recently closed STRATUM RCT. He is Principal Investigator of the Singapore NMRC Flagship Program in Liver Cancer and the prospective ELEGANCE cohort study.

Jens Samol

Tan Tock Seng Hospital | Singapore

Dr Samol is the Clinical Lead for Thoracic Cancers, Lymphoma (within Medical Oncology) and Sarcoma as well as the Clinical Lead for Genetic Counselling and Clinical Cancer Genetics & Genomics Service at TTSH. He is the Director for Clinical Trials (CRIO), Co-Director (TTSH) for P.H.Feng Research Centre and is the Clinical Research Lead of the Medical Oncology Department at TTSH. Dr Samol holds a faculty appointment as an Assistant Professor at Lee Kong Chian School of Medicine, Singapore, as well as an Assistant Professor of Oncology at Johns Hopkins University School of Medicine, Baltimore, USA. He treats patients with all types of solid cancers and lymphoid neoplasms. He has a particular interest in Thoracic Cancers, Gastrointestinal Cancers (including HIPEC), Head & Neck Cancers, Sarcoma, and Lymphoma.

Elizabeth Smyth

Oxford University Hospitals | United Kingdom

Dr. Elizabeth Smyth is a Medical Oncologist and Gastrointestinal Oncology Lead in Oxford. She also serves as Clinical Lead for the Oxford Clinical Trials Office and Deputy Lead for the Oxford Experimental Cancer Medicine Centre. Her career has been defined by a commitment to improving outcomes for patients through high-quality clinical trials, impactful translational research, and international collaboration in oncology education.

Elizabeth Chuk

National University Cancer Institute | Singapore

Dr Elizabeth Chuk graduated from the medical school of The Chinese University of Hong Kong, and obtained her Clinical Oncology fellowship from the Royal College of Radiologists (UK) and The Hong Kong College of Radiologists. Dr Chuk completed a clinical research fellowship in Gynaecological malignancy from the Department of Radiation Oncology at the Princess Margaret Cancer Centre, Toronto in year 2023 - 2024. During her fellowship, she gained extensive experience in MRI-guided interstitial brachytherapy for gynaecological cancers. In the same year, she was awarded the 2024 Postgraduate Medical Trainee Leadership Award from the University of Toronto. Dr Chuk is currently practising as an associate consultant in the Department of Radiation Oncology at the National University Cancer Institute, Singapore. Her subspecialty interests are in Gynaecological, Breast and Gastrointestinal cancers, palliative radiation and brachytherapy. She is also serving in the geriatric oncology (GOLDEN) programme in NUH. Dr Chuk is actively involved in clinical research and has presented in international conferences and published her work in peer-reviewed journals.

Claramae Chia

National Cancer Centre Singapore | Singapore

A/Prof Claramae Chia is a Senior Consultant in the Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT) at the National Cancer Centre Singapore. A surgical oncologist with a subspecialty focus on peritoneal surface malignancies, she received advanced training in Singapore and France under Professor Olivier Glehen. She played a key role in establishing the SPRinT department in 2019 and has led innovative initiatives, including the introduction of Pressurised Intraperitoneal Aerosolised Chemotherapy (PIPAC). A/Prof Chia is actively involved in clinical and translational research, with over 70 publications, and is a dedicated educator and mentor to future surgeons.

Aru Sudoyo

Indonesian Society of Hematology Medical Oncology | Indonesia

Prof. Aru holds a Medical Oncology Consultant Hematology degree at the University of Indonesia. He is the President of The Indonesian Society of Hematology Medical Oncology (ISHMO). He also serves on the Advisory Board of the Indonesian Internal Medicine Specialist Association (PB PAPDI). He is also a member of the Executive Board of the World Association of Internal Medicine and Member of the Management of the Indonesian Cancer Foundation (YKI).

Heinz-Josef Lenz

University of Southern California Norris Comprehensive Cancer Center | USA

Heinz-Josef Lenz, M.D., FACP, is the University Professor of Medicine, Population and Health Sciences and Cancer Biology Associate at the USC Norris Comprehensive Cancer Center (NCCC). He hold the J Terrence Lanni Chair for Cancer Research in the Division of Medical Oncology and Co-Director of the Center for Cancer Drug Development at USC Norris Comprehensive Cancer Center. He is Visiting Professor at the Milken Translational Research Institute at CALTECH. An active researcher, Dr. Lenz’s National Cancer Institute-funded laboratory is developing novel agents in his preclinical models in GI cancer. Lenz, a transformational clinical investigator and translational scientist, was the first to lead the first prospective randomized Phase II trials using gene expression from FFPE specimens. He also discovered that primary tumor location of colorectal cancer (CRC) is an independent predictive and prognostic marker, now in the NCNN guidelines. His paper on Consensus Molecular Subtyping identified novel subgroups that are predictive and prognostic in CRC, now used globally in drug development. He is the Co-PI of the UG1 CA 062505, currently leads the NCCC site for the NCI UM1 (CA186717 with City of Hope, UC Davis, University of Chicago, Case Western and Stanford) and he is a Member of NCI Investigational Drug Steering Committee. Dr. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials. He together with Dr. Carpten received a Moonshot Colon Cancer Research Grant from the NCI (U2C CA252971). Dr. Lenz earned his M.D. degree at the Johannes-Gutenberg Universität in Mainz, Germany. In 1991, he completed his internship, residency, and fellowship training at the Eberhardt Karls Universität in Tübingen, Germany. He obtained special fellowship training at Universität Wien (Austria), George Washington University and Harvard Medical School. In 1991, he received the prestigious Research Fellowship Award from the “Deutsche Krebshilfe” (Bonn, Germany). He completed his research fellowship in biochemistry and molecular biology at the USC Norris Comprehensive Cancer Center before joining the faculty of USC in 1994. He was awarded a Career Development Award from STOP CANCER (1994-1997). Based on his research, he also received a Young Investigator Award from the American Society of Clinical Oncology (ASCO) in 1994. In 1995, Dr. Lenz was selected for the prestigious ASCO Career Development Award, as well as a NIH Mid-Career Development Award. He is Senior Member of the National Academy of Inventors and was awarded USC University Professor in 2026. He has published over 760 peer reviewed manuscripts with an h-index of 133.

Cathy Eng

Vanderbilt-Ingram Cancer Center | USA

Cathy Eng, MD, FACP, FASCO is the David H. Johnson Chair in Surgical and Medical Oncology, Professor of Medicine in Hematology and Oncology, Director of Strategic Relations and Research Partnerships, and Executive Director of the Young Adult Cancers Program at the Vanderbilt-Ingram Cancer Center. A recognized international leader in gastrointestinal oncology, she specializes in colorectal, anal, and appendiceal cancers, with particular interests in young-onset colorectal cancer and immunotherapy for HPV-associated malignancies. Prior to joining Vanderbilt in 2019, she spent over 17 years at MD Anderson Cancer Center. Dr. Eng has held numerous national leadership roles within ASCO, ECOG, SWOG, and the NCI, contributing significantly to advancing GI cancer research and clinical care.

Ekaphop Sirachainan

Ramathibodi Comprehensive Cancer Center (RCCC) | Thailand

"Dr. Ekaphop Sirachainan is an Associate Professor in the Division of Oncology, Department of Medicine, at the Faculty of Medicine, Ramathibodi Hospital, Mahidol University in Bangkok, Thailand. He has been serving as the Chairman of the Ramathibodi Comprehensive Cancer Center since 2020. Dr. Sirachainan has extensive research experience and has authored over 40 original articles and contributed to more than 11 book chapters. His research focuses on colorectal cancer and other areas in GI oncology. He is a member of the Royal College of Physicians (Thailand), the Asian Oncology Society (AOS), the European Society of Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO). Previously, he served as the President of the Thai Society of Clinical Oncology (TSCO) and currently holds position as the chairman of GI oncology research group (TSCO GIOG). "

Jeanne Tie

Peter MacCallum Cancer Centre | Australia

Professor Jeanne Tie is a consultant medical oncologist and Lower GI Research Lead at Peter MacCallum Cancer Centre, and Senior Research Fellow at WEHI. Trained at the University of Otago, she has built a research career focused on colorectal cancer therapeutic trials and the clinical application of ctDNA. Her 2016 Science Translational Medicine paper, recognised by ASCO as a major advance, showed ctDNA could detect residual disease after surgery, leading to the practice-changing DYNAMIC trial (NEJM, 2022). She has published 170+ papers with 23,000+ citations, chairs the GI Cancer Trials Lower GI Working Party, and serves on the ESMO Colorectal Guideline Panel and ARCAD steering committee.

Ammar Sarwar

University of Pittsburgh Medical Center | USA

Professor Ammar Sarwar is a distinguished interventional radiologist and academic leader, currently serving as Chief of Interventional Radiology at UPMC. With over a decade of experience in minimally invasive image-guided therapies, he has held key clinical and leadership roles at Beth Israel Deaconess Medical Center, where he continues to practice as an Interventional Radiologist. Professor Sarwar also serves as Chair of Economics for the Society of Interventional Radiology, contributing to healthcare policy and value-based care initiatives. His expertise spans interventional oncology, vascular interventions, and advancing patient-centered innovation in radiology.

Isaac Seow-En

Department of Colorectal Surgery, Singapore General Hospital | Singapore

Dr Isaac Seow-En is a Senior Consultant Colorectal Surgeon at Singapore General Hospital and the National Cancer Centre Singapore, specialising in advanced minimally invasive and transanal colorectal surgery. Fellowship-trained in Taiwan, he is internationally recognised for work in NOSES, TAMIS, and TaTME for rectal cancer. With 90 peer-reviewed publications, he serves on journal editorial boards and leads the Singapore Branch of the International NOSES Alliance, advancing surgical innovation and outcomes research.

Chee Cheng Ean

National University Cancer Institute , Singapore | Singapore

Adj A/Prof Chee Cheng Ean is the Executive Director of the National University Cancer Institute, Singapore. In this role, she provides leadership and direction, and is responsible for implementing strategic initiatives for NCIS (pronounced N-CIS), which is the only public, academic cancer center in Singapore treating both pediatric and adult cancers in one facility. Adj A/Prof Chee is also a senior consultant, gastrointestinal (GI) oncologist and clinician investigator. Her portfolio includes clinical and research initiatives in precision oncology and clinical trials involving novel therapeutics in GI cancers which have been awarded institutional and national grant funding. She also leads the cancer survivorship programme at NCIS and is a proponent of value-based healthcare initiatives.

Jimmy So

National University Cancer Institute of Singapore (NCIS) | Singapore

Prof Jimmy So is a Professor at the Yong Loo Lin School of Medicine, National University of Singapore, and serves as Head of General Surgery (Upper Gastrointestinal Surgery) at the National University Hospital, as well as Head of Surgical Oncology at the National University Cancer Institute, Singapore. An internationally recognized surgeon-scientist, his expertise spans upper gastrointestinal surgery, surgical oncology, minimally invasive surgery, therapeutic endoscopy, and bariatric surgery. Prof So has authored over 300 peer-reviewed publications and secured more than S$30 million in research funding. He is a pioneer of advanced gastric cancer treatments in Singapore and recipient of the prestigious Peritoneal Prize in 2020.

Lim Yueh Ni

Pantai Hospital Penang | Malaysia

Dr. Lim is a distinguished alumna of AIMST University (2009), she earned her Master in Clinical Oncology from the University of Malaya in 2018, gazetted at the National Cancer Institute and went on to serve at Sarawak General Hospital prior to joining Pantai Hospital Penang. Her career is defined by a deep commitment to advancing research in hepatocellular, lung and breast cancers. She is currently an EXCO member of Malaysian Oncological Society. She played a pivotal role in the Sarawak GH-ASCO International Cancer Corps and has co-organized high-impact ASCO educational MDTs across neuro-oncology and women's cancers. Her professional excellence is further highlighted by her selection for the ASCO Leadership Development Program (Asia Pacific) in 2024. She has completed her Clinical Scholars program at the National Taiwan University Cancer Center in 2026, focusing in advance care for hepatobiliary, head and neck, nasopharyngeal, colorectal and lung cancer.

Tan Hon Lyn

OncoCare Cancer Centre | Singapore

Dr. Tan Hon Lyn is a Senior Medical Oncologist with a special interest in gastrointestinal cancers, including gastric, colorectal, pancreatic, liver, biliary tract cancers, gastrointestinal stromal tumours (GISTs), and neuroendocrine tumours. She graduated from the National University of Singapore, where she was awarded the prestigious Lee Kuan Yew Gold Medal. Prior to private practice, she served as Consultant at the National University Cancer Institute, Singapore (NCIS). Dr. Tan is actively involved in clinical research, with publications in leading journals such as the Journal of Clinical Oncology and Clinical Cancer Research. She also currently serves as Honorary Secretary of the Singapore Society of Oncology.

Vashishth Maniar

M|O|C Cancer Care & Research Centre | India

Dr. Vashishth Maniar is a leading Medical and Paediatric Hemato-Oncologist based in Mumbai, with over a 13 years of experience in the diagnosis and treatment of solid tumors, hematological malignancies, and stem cell transplantation. He completed his MBBS from D.Y. Patil Medical College, Mumbai, followed by an MD in General Medicine from Lokmanya Tilak Municipal Medical College and a DM in Medical Oncology and Hemato-Oncology from the Gujarat Cancer and Research Institute, where he was awarded a Gold Medal. Dr. Maniar is an ESMO Board-Certified Medical Oncologist and has received advanced training in lymphoma and leukemia management at the University of Giessen, Germany. He is widely recognized for his academic excellence, clinical expertise, and contributions to oncology education and research, and is an active member of ASCO, ESMO, and ISMPO.

Yong Wei Peng

National University Cancer Institute, Singapore at the National University Hospital | Singapore

Dr Yong Wei Peng is the associate director (research) and senior consultant from National University Cancer Institute, Singapore at the National University Hospital. He obtained his medical degree and postgraduate training in University of Aberdeen, Scotland. After completing an oncology fellowship at the National University Hospital, he was awarded the A*star international clinical pharmacology fellowship at the University of Chicago. Upon his return to Singapore, he was awarded the Clinician Scientist Award to further his research into personalized therapy. In addition, Dr Yong leads the therapeutic arm of the Singapore Gastric Cancer Consortium and chairs the National Health Group Domain Specific Review Board. His clinical and research interests are gastrointestinal cancer and drug development.

Dawn Chong

National Cancer Centre Singapore | Singapore

Dr Dawn Chong is a Senior Consultant in the Division of Medical Oncology at the National Cancer Centre Singapore and specializes in gastrointestinal cancers. Dr Chong completed a fellowship in clinical and translational cancer epidemiology at the Massachusetts General Hospital and obtained a degree in Master of Public Health at the Harvard T.H. Chan School of Public Health. She was awarded the National Medical Research Council Transition Award for her research that focuses on metabolites in colorectal cancer. Dr Chong is an Assistant Professor of the Duke-NUS Medical School and a clinical lecturer of the Yong Loo Lin School of Medicine and has been actively involved in the training of undergraduates and young clinicians.

Kim Guowei

Crest Surgical Practice, Mount Elizabeth Hospital | Singapore

Dr. Kim Guowei is a leading upper gastrointestinal and minimally invasive surgeon with expertise in robotic surgery, advanced endoscopy, and surgical innovation. Following advanced training in laparoscopic and robotic surgery in South Korea, he became recognized for pioneering innovations, including robotic upper GI surgery, telesurgery, and PIPAC. Prior to private practice, he served as Senior Consultant and Program Director at NUHS. He is currently the President of OMSSS, Vice-Chair of the Section of Upper GI Surgery (Chapter of General Surgeons), Board Member of RS3, and is an Adjunct Assistant Professor at NUS. He is a frequent international speaker and proctor on robotic surgery and advanced surgical techniques.

Kong Hwai Loong

Icon Cancer Centre and NUS | Singapore

Dr Kong Hwai Loong is a Medical Oncologist at the Icon Cancer Centre Singapore. He is an Adjunct Associate Professor at National University of Singapore (NUS) and a visiting specialist in medical oncology at the National University Healthcare System (NUHS). Dr Kong was previously the Executive Director of the Biomedical Research Council (BMRC) and Deputy Managing Director for the Agency for Science, Technology and Research (A*STAR). He was awarded the Singapore Youth Award for his research on cancer gene therapy. Dr Kong specialises in the diagnosis and treatment of adult cancers. He also lectures regularly on oncology-related topics.

Koo Si-Lin

National Cancer Centre Singapore | Singapore

Dr. Koo Si-Lin is a Senior Consultant Medical Oncologist specialising in gastrointestinal cancers with a focus on colorectal cancer. Her clinical practice centres on providing comprehensive care for patients with gastrointestinal malignancies. In addition to patient care, she is actively involved in clinical research, serving as Principal Investigator in various trials in colorectal cancer. Her research work includes collaborations with various academic institutions, contributing to the field through peer-reviewed publications. At NCCS, she combines clinical care with research to support evidence-based treatment approaches for patients with gastrointestinal cancers.